DWA
LRMR icon

Dorsey Wright & Associates’s Larimar Therapeutics LRMR Stock Holding History

Dorsey Wright & Associates’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-139
Closed -$19K – 317
2018
Q3 		$19K Buy
+139
New +$16.9K ﹤0.01% 173

Other funds holding LRMR

GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Dorsey Wright & Associates's LRMR Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Larimar Therapeutics (LRMR) in Q4 2018, closing a stake of 139 shares — an estimated $19K sold.

Dorsey Wright & Associates first reported a position in LRMR in Q3 2018 and held it in 1 quarter. The position peaked at $19K in Q3 2018. 94 funds tracked by Wall St. Rank hold LRMR as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Larimar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 139 Larimar Therapeutics shares in Q4 2018, an estimated $19K.
  • Dorsey Wright & Associates first reported a position in Larimar Therapeutics in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Larimar Therapeutics position peaked at $19K in Q3 2018.
  • 94 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.